procainamide
procainamide: developed by 1 company · 1 FDA decision.
procainamide evidence translation
What we can confirm
1 FDA record
What it means
What to watch
Prepared research question
How could procainamide → NEXS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
Development Pipeline (2)
| Company | Phase |
|---|---|
| NEXUS BIOPHARMA INC (NEXS) | Approved |
| NEXUS BIOPHARMA INC (NEXS) | Approved |
FDA Decisions1 records
Frequently asked questions
Who is developing procainamide?
procainamide is being developed by NEXUS BIOPHARMA INC.
What is procainamide's latest FDA decision?
The most recent tracked FDA decision for procainamide is Approval for INDICATIONS AND USAGE Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other ant, dated October 13, 2017.